The strategies to protect against the disrupted blood-brain barrier (BBB) in HIV-1 infection are not well developed. Therefore, we investigated the potential of peroxisome proliferator-activated receptor (PPAR) agonists to prevent enhanced BBB permeability induced by HIV-1-specific protein Tat. Exposure to Tat via the internal carotid artery (ICA) disrupted permeability across the BBB; however, this effect was attenuated in mice treated with fenofibrate (PPARa agonist) or rosiglitazone (PPARg agonist). In contrast, exposure to GW9662 (PPARg antagonist) exacerbated Tat-induced disruption of the BBB integrity. Increased BBB permeability was associated with decreased tight junction (TJ) protein expression and activation of ERK1/2 and Akt in brain microvessels; these effects were attenuated by cotreatment with fenofibrate but not with rosiglitazone. Importantly, both PPAR agonists also protected against Tat-induced astrogliosis and neuronal loss. Because disruption of TJ integrity has been linked to matrix metalloproteinase (MMP) activity, we also evaluated Tat-induced effects in MMP-9-deficient mice. Tat-induced cerebrovascular toxicity, astrogliosis, and neuronal loss were less pronounced in MMP-9-deficient mice as compared with wild-type controls and were further attenuated by PPAR agonists. These results indicate that enhancing PPAR activity combined with targeting MMPs may provide effective therapeutic strategies in brain infection by HIV-1.
INTRODUCTION
Highly active antiretroviral therapy significantly prolongs the lives of HIV-infected patients. While the overall severity of HIVassociated neurocognitive disorders decreased reflecting a better virologic control, neurocognitive impairment remained prevalent or even increased. 1 This phenomenon may be related to the fact that HIV-infected patients live longer and aging becomes an important comorbidity factor contributing to neurocognitive deficits in HIV infection. 2 In addition, the brain is considered to be an important HIV reservoir, which is relatively poorly accessed by antiretroviral drugs; 1 thus, HIV may replicate in the brain even though HIV replication is suppressed in the periphery. Another hypothesis explaining the persistent high prevalence of neurocognitive dysfunction is related to the toxicity of antiretroviral drugs. For example, protease inhibitors induce alterations in plasma lipids and insulin levels that place patients at the risk for coronary heart disease and cerebral vascular disease. 3, 4 Highly active antiretroviral therapy, including nucleoside reverse transcriptase inhibitors, can increase the intracellular reactive oxygen species production, 5 supporting the rationale for supplementary antioxidative therapy.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that are considered to be critical rescue molecules, which can downregulate activation of redox-responsive transcription factors and exert antiinflammatory effects. We and others observed that PPARs can protect against HIV-1-induced neuroinflammation and dysfunction of brain endothelial cells partly by inhibition of proinflammatory responses. [6] [7] [8] Study indicates that PPARg agonist rosiglitazone may also partly correct lipoatrophy in patients with HIV infection. 7 Rosiglitazone can reduce HIV-1 replication in lymphocytes and brain macrophages, offering a new therapeutic intervention to HIV-1 infection in central nervous system (CNS). 9 HIV-1 infection is associated with increased expression and activity of matrix metalloproteinases (MMPs) in the CNS, with elevated levels of MMP-9 being reported in cerebrospinal fluid of HIV-1-infected patients. 10, 11 Imbalance between MMPs and endogenous TIMPs (tissue inhibitors of MMPs) may contribute to HIV-associated pathology by inducing remodeling of the extracellular matrix. 12 Activation of ERK1/2-and JNK-NF-kB cascades by reactive oxygen species appears to be essential for MMP-9 upregulation. 13 We reported that overexpression of PPARs attenuated HIV-1-mediated dysregulation of tight junctions (TJs) by inhibiting MMP activity and caveolae-associated ERK and Akt signaling in vitro. 14, 15 However, MMP activity was also linked to neuronal loss. 16 In fact, it was showed that Tat-induced neurotoxicity can be prevented by an MMP inhibitor, prinomastat, and upregulation of TIMP-1 by glia in acute HIV-1 infection may exhibit neuroprotection.
Because targeting both PPAR and MMP activities may alleviate HIV-1-induced neuropathology, we focused the present study on the interactions of these factors in a model of HIV cerebral toxicity induced by HIV-specific protein Tat. Our data indicate that Tat-induced disruption of the blood-brain barrier (BBB), alterations in TJ protein expression as well as neuronal loss and astrogliosis can be attenuated by PPAR agonists and MMP-9 deficiency. Importantly, combining these factors offered superior therapeutic advantages.
MATERIALS AND METHODS

Animals and Treatment
Wild-type (WT) (FVB/NJ) and MMP-9-deficient mice (3 months old, males), generated on the FVB/NJ genetic background, were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All experiments were performed in strict adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures and protocols were approved by the University of Kentucky Institutional Animal Care and Use Committee. Mice (n ¼ 3 per group) were administered intraperitoneally once daily for 7 days with fenofibrate (PPARa agonist, 100 mg/kg), rosiglitazone (PPARg agonist, 10 mg/kg), MK886 (PPARa antagonist, 3 mg/kg), or GW9662 (PPARg antagonist, 1 mg/kg). Fenofibrate and rosiglitazone were obtained from Sigma (St. Louis, MO, USA) and MK886 and GW9662 from Alexis Biochemicals (San Diego, CA, USA). All PPAR agonists and antagonists were dissolved in dimethyl sulfoxide/saline (1:10) .
At the end of the treatment period with PPAR agonists, HIV-1-specific Tat protein (or vehicle in control mice) was delivered via the internal carotid artery (ICA) and allowed to circulate for 24 hours as established by our group. 18 Under these experimental conditions, administration of heat inactivated Tat has no biologic activity. 19 The route of Tat delivery via the ICA is a model of Tat being released from HIV-infected blood-borne cells and affecting the BBB from the luminal site of the brain endothelium. In specific experiments, Tat was administered every other day for a total of three injections. Recent study estimated Tat levels up to 40 ng/mL in the cerebrospinal fluid of HIV-infected individuals on antiretroviral therapy. 20 We exposed mice to Tat based on dose-dependent experiments in which 20 mg/injection was effective in disruption of the BBB. 21 However, only a small fraction of administered Tat is likely to be bioavailable, as Tat can be sequestered by endogenous antibodies and extracellular matrices. In addition, Tat polymerizes easily due to the presence of seven cysteine residues, but only the monomeric form is biologically active. Furthermore, the Tat molecule has five arginine residues that make the protein stick easily to plastic and glass, further decreasing its bioavailability.
Blood-Brain Barrier Permeability Assay
Blood-brain barrier integrity was assessed as described earlier. 21 Briefly, mice were injected intraperitoneally with 200 mL sodium fluorescein (6 mg/mL, in sterile phosphate-buffered saline, PBS), which was allowed to circulate for 20 minutes. Mice were anesthetized with isoflurane in oxygen, blood was collected through heart puncture, and centrifuged for segregating plasma. Mice were perfused through the left ventricle with 30 mL PBS. Brains were homogenized in PBS (1:10, w/v) and centrifuged at 14,000 g for 2 minutes. Then, 15% trichloroacetic acid (500 mL) was added to the supernatants (500 mL) and the mixtures were at 1,000 g for 10 minutes. The supernatants (500 mL) were neutralized with 125 mL NaOH (5 mol/L). Fluorescence was measured in 200 mL aliquots of neutralized brain homogenates using 485 nm and 530 nm for excitation and emission, respectively. Plasma was diluted with PBS (1:100) and measured for fluorescence intensity using the same setting. The BBB permeability was calculated as the ratio of sodium fluorescein in the brain to plasma.
Expression of Akt, ERK1/2, and Tight Junction Proteins in Brain Microvessels
Brain microvessels were isolated 24 hours after Tat injection using a previously described procedure. 22 Briefly, mice were anesthetized with isoflurane in oxygen, and perfused with 15 mL saline. After decapitation, the brains were removed and immediately immersed in ice-cold isolation buffer with Complete Protease Inhibitor (Roche, Indianapolis, IN, USA). Choroid plexus, meninges, cerebellum, and brain stem were removed; the brains were homogenized in isolation buffer with Complete Protease Inhibitor, followed by dextran gradient centrifugation. The obtained pellets containing microvessels were either smeared on slides for immunofluorescent staining or resuspended in 0.5 mL of 6 mol/L urea lysis buffer (6 mol/L urea, 0.1% Triton X-100, 10 mmol/L Tris, pH 8.0, 5 mmol/L MgCl 2 , 5 mmol/L EDTA, 150 mmol/L NaCl) with Complete Protease Inhibitor for immunoblotting analyses. Protein samples were either immediately used or stored at À 801C. 22 For immunoblotting, protein samples were separated on 4% to 15% TrisHCl Ready SDS-polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA), blotted onto polyvinyl difluoride membranes (Bio-Rad Laboratories), and incubated with the respective antibodies. 18, 22 Anti-zonula occludens-1 (ZO-1) and claudin-5 antibodies were purchased from Zymed (San Francisco, CA, USA). Anti-total-ERK1/2 (T-ERK1/2, p44/42 MAPK), phospho-ERK1/2 (pERK1/2), and phospho-Akt (Ser473; D9E) antibodies were from Cell Signaling (Danvers, MA, USA). Anti-actin antibody was from Sigma. Anti-Akt1/2/3 (H-136) and all secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immunoblots were analyzed using an ECL Western blot detection kit (GE Healthcare Life Sciences, Piscataway, NJ, USA) and proteins of interest were semiquantitated with the ImageJ software (NIH, Baltimore, MD, USA).
For immunofluorescent staining, brain microvessels smeared on slides were fixed for 10 minutes at 951C, followed by incubation with 3% formaldehyde in PBS for 10 minutes at 251C. Slides were washed five times with PBS, permeabilized with 0.1% Triton X-100 for 30 minutes, rewashed five times in PBS, and blocked in 1% bovine serum albumin (BSA) in PBS for 30 minutes at 251C. Samples were then incubated with an individual primary antibody (1:500 dilutions in 1% BSA in PBS) overnight at 41C. Slides were washed with PBS and incubated with Alexafluor 568-conjugated antimouse IgG or Alexafluor 488-conjugated anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA) (1:1,000 dilution in 1% BSA in PBS) for 1 hour at 371C. After final washing with PBS, slides were mounted with ProLong Gold Antifade reagent containing 4 0 ,6-diamidino-2-phenylindole (Invitrogen) to visualize the nuclei. The immunofluorescent images were evaluated and captured using confocal microscopy. Figure 1 . Peroxisome proliferator-activated receptor (PPAR) agonists protect against HIV-1 Tat-induced disruption of blood-brain barrier (BBB) integrity. Wild-type (FVB/NJ) mice were administered intraperitoneally with vehicle, fenofibrate (PPARa agonist, 100 mg/kg), rosiglitazone (PPARg agonist, 10 mg/kg), MK886 (PPARa antagonist, 3 mg/kg), or GW9662 (PPARg antagonist, 1 mg/kg) once a day for 1 week, followed by injection with Tat (20 mg/mouse) via the internal carotid artery (ICA). The BBB permeability was assessed 24 hours after Tat administration using sodium fluorescein as the marker, which macroscopically stains the brains with highly disrupted BBB in yellow (upper panel). Quantification of the effects of Tat and PPAR modulators on the BBB permeability are shown as a bar graph. Results are the mean ± SEM. ***Significantly different as compared with vehicle-treated controls at ***Po0.001.
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Determination of Astrogliosis and Neuronal Loss
Expression of NeuN in the brains was analyzed by immunoblotting and immunofluorescence as a marker of neuronal loss. For immunoblotting, the brains were homogenized in ice-cold RIPA lysis buffer (Santa Cruz Biotechnology) and centrifuged at 15,000 g for 15 minutes. The aliquots of supernatants (20 mg of protein) were loaded onto 4% to 15% Tris-HCl Ready SDS-polyacrylamide gel (Bio-Rad Laboratories). Mouse anti-NeuN antibody was purchased from Millipore (Kankakee, IL, USA); rabbit anti-GFAP antibody and anti-actin antibody were from Sigma; and all secondary antibodies were from Santa Cruz Biotechnology.
For immunostaining analyses, the brains were removed and serial coronal sections (10 mm each) in optimal cutting temperature compound were prepared. The staining was performed as previously described. 22 The brain sections were blocked with 3% BSA in PBS and incubated with mouse anti-NeuN (1:500; Millipore) or rabbit anti-GFAP antibodies (1:500; Sigma) at 41C overnight. After removal of primary antibodies, the sections were washed with PBS and incubated with Alexafluor 568-conjugated antimouse IgG or Alexafluor 488-conjugated anti-rabbit IgG (Invitrogen) (1:1,000 dilution in 1% BSA in PBS) for 1 hour at 371C. After final washing with PBS, slides were mounted with ProLong Gold Antifade reagent containing 4',6-diamidino-2-phenylindole (Invitrogen) to visualize the nuclei. The immunofluorescent images were evaluated and captured using confocal microscopy.
Image Quantification and Statistical Analysis
Quantification of image data was performed using the image analysis programs ImageJ (version 1.41, NIH, Baltimore, MD, USA). To minimize the variation in fluorescence intensities from image to image, we compared the absolute numbers of pixels in images, which were prepared in the same experiment with the same pool of antibodies and were taken under the identical instrument setting. Routine statistical analysis was completed using Sigma-Stat 2.03 (SPSS, Chicago, IL, USA). One-or two-way ANOVA was used to compare mean responses among the treatments. Statistical probability of Po0.05 was considered as significant. All experiments and analyses were repeated at least three times. 23 however, the protective strategies against this effect are poorly developed. Our initial series of experiments focused on the effects of PPAR activity modulators on Tat-induced alterations of the BBB permeability in WT mice. The analyses were performed using sodium fluorescein flux from the vasculature into the brain parenchyma. In cases of severely compromised BBB integrity, increased levels of sodium fluorescein in brain tissue result in yellowing the brains (Figure 1 , upper panel). As quantified in Figure 1 , exposure to Tat markedly increased BBB permeability. Importantly, pretreatment with PPARa agonist, fenofibrate, or PPARg agonist, rosiglitazone, attenuated Tat-induced BBB hyperpermeability. In contrast, Tat-induced disruption of the BBB integrity was further exacerbated by PPARg antagonist, GW9662. Cotreatment with PPARa antagonist, MK886, did not affect Tat-mediated changes in BBB permeability.
Peroxisome Proliferator-Activated Receptor Agonists Differentially Attenuate Tat-Induced Alterations in Tight Junction Protein Expression Tight junctions, which regulate paracellular BBB permeability, are susceptible to Tat-induced disruption via MMP-mediated mechanisms.
14,24 Therefore, we evaluated the influence of PPAR agonists on Tat-induced changes in TJ expression levels in both WT and MMP-9-deficient mice. To focus our studies on cerebrovascular toxicity of Tat, the analyses were performed on isolated brain microvessels. We evaluated the expression levels of claudin-5, a transmembrane TJ protein, and TJ-associated protein, ZO-1, which links the transmembrane TJ proteins to the actin cytoskeleton.
Exposure to Tat for 24 hours downregulated claudin-5 and ZO-1 levels in the brain microvessels of WT. The examples of these effects are illustrated in Figure 2A . While the basal levels of TJ proteins were lower in MMP-9 À / À mice as compared with WT controls, treatment with Tat decreased claudin-5 but not ZO-1 levels in MMP-9-deficient mice ( Figures 2B and 2C ). Preexposure to PPAR agonists had differential effects on TJ protein expression as only fenofibrate, but not rosiglitazone, attenuated Tat-induced alterations in claudin-5 ( Figure 2B ) and ZO-1 ( Figure 2C ) expression in WT mice. Moreover, treatment with fenofibrate plus Tat increased TJ expression above control levels in MMP-9 À / À mice ( Figures 2B and 2C ).
Peroxisome Proliferator-Activated Receptor g Protects Against TatInduced Activation of the ERK1/2 and Akt Signaling The ERK1/2 and Akt signaling was linked to the regulation of TJ protein integrity; 15 therefore, we also evaluate these pathways in the present study. Exposure to Tat markedly induced phosphorylation of ERK1/2 ( Figure 3A) and Akt ( Figure 3B ) in brain microvessels of WT mice. In contrast, Tat induced only minimal effects on ERK1/2 phosphorylation and had no influence on Akt phosphorylation in MMP-9-deficient mice. Consistent with the data on TJ expression, exposure to fenofibrate, but not rosiglitazone, attenuated Tat-induced activation of ERK1/2 and Akt in WT mice. In MMP-9-deficient mice, both fenofibrate and rosiglitazone protected against Tat-induced phosphorylation of ERK1/2; however, fenofibrate enhanced Akt phosphorylation in these animals.
Peroxisome Proliferator-Activated Receptor Agonists Protect Against HIV-1 Tat-Induced Reactive Astrogliosis One of the hallmarks of HIV-1 CNS infection is reactive astrogliosis, associated with increased GFAP expression. In addition, Tat was showed to activate GFAP in astrocytes. 25, 26 To evaluate whether PPAR agonists protect against Tat-induced astrogliosis, WT and MMP-9-deficient mice were pretreated with fenofibrate or rosiglitazone, followed by repeated Tat injections (20 mg/mouse, 48 hours apart) into the ICA. Initial exposure to a single dose of Tat for 24 hours did not induce GFAP overexpression (data not shown). However, the repeated administration of Tat stimulated GFAP expression at day 7, as determined by immunostaining ( Figure 4A ) and immunoblotting ( Figure 4B ). While reactive astrogliosis in response to Tat was observed both in WT and in Figure 3 . Peroxisome proliferator-activated receptor g (PPARg) protects against HIV Tat-induced activation of the ERK1/2 and Akt signaling. Wild-type (WT, FVB/NJ) and matrix metalloproteinase-9 (MMP-9)-deficient mice were administered with PPAR agonists, followed by exposure to Tat for 24 hours as in Figure 1 . Total ERK1/2 (T-ERK1/2) and phosphorylated ERK1/2 (pERK1/2) (A) and Akt (B) in brain microvessels were detected by immunoblotting. Molecular weight of ERK1/2 and Akt bands is indicated on the graph. The two bands in the p-ERK and T-ERK panels represent ERK1 (44 kDa) and ERK2 (42 kDa), respectively. The two bands in p-Akt and T-Akt panels represent Akt1 (60 kDa) and Akt2 (57 kDa), respectively. Results are the mean ± SEM. *Significantly different as compared with vehicle-treated controls in WT or MMP-9-deficient mice at Po0.05, **Po0.01, or ***Po0.001. PPARs attenuate cerebrovascular toxicity of HIV W Huang et al MMP-9-deficient mice, the overall effects were markedly less pronounced in mice with MMP-9 deficiency ( Figure 4A ). Tatinduced GFAP overexpression was inhibited by fenofibrate and rosiglitazone in WT mice ( Figures 4A and 4B) . In contrast, only rosiglitazone, but not fenofibrate, attenuated Tat-induced astrogliosis in MMP-9 À / À mice ( Figure 4B ).
Peroxisome Proliferator-Activated Receptor Agonists Protect Against HIV Tat-Induced Neuronal Loss Neuronal injury underlies the development of cognitive dysfunction frequently observed in HIV-1 brain infection. 27 Therefore, we evaluated the effects of Tat and PPAR agonists on neuronal loss using NeuN as a specific neuronal marker. Exposure to Tat induced an evident neuronal loss in the cerebral cortex of WT mice 24 hours after Tat administration as determined by both immunostaining ( Figure 5A ) and immunoblotting ( Figure 5B ). Importantly, these effects were alleviated by pretreatment of mice with fenofibrate or rosiglitazone ( Figures 5A and 5B) . In contrast to WT mice, Tat did not induce a visible neuronal loss in MMP-9 animals. In addition, fenofibrate increased NeuN immunostaining in these mice above control levels ( Figures 5A and 5B) .
DISCUSSION
Increased tissue oxidative stress and upregulation of MMPs induced by Tat contribute to HIV-1-induced BBB disruption and the development of AIDS-associated dementia at later stages of HIV infection. [14] [15] [16] Oxidative stress may also be an early step in the mechanism of Tat neurotoxicity. 16 Peroxisome proliferator-activated receptor are ligand-activated transcription factors that can downregulate activation of redox-responsive transcription factors 15 and exert antiinflammatory effects. 6 Therefore, therapeutic intervention with PPAR agonists appears to be an attractive option in HIV. Indeed, the results of the present study indicated that both PPARa and PPARg agonists protected against Tatinduced downregulation of TJ proteins; although fenofibrate (PPARa agonist) was more effective in preventing activation of ERK1/1 and Akt in WT mice. These differential effects of PPAR agonists may reflect their role in metabolism and antioxidative Figure 4 . Peroxisome proliferator-activated receptor (PPAR) agonists protect against HIV Tat-induced reactive astrogliosis. Mice were treated with PPAR agonists as in Figure 1 , followed by repeated injections with Tat (20 mg/injection, administered every other day for the total of three injections) and determination of GFAP expression as the marker of astrogliosis by immunostaining (A) or immunoblotting (B). Images reflect representative data from at least three experiments. Analyses were performed 7 days after the first injection of Tat in the cerebral cortex (A) or the whole brain homogenates (B). Results are the mean ± SEM. *Significantly different as compared with vehicle-treated controls in wild-type (WT) or MMP-9 À / À mice at Po0.01, **Po0.01, or ***Po0.001.
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PPARs attenuate cerebrovascular toxicity of HIV W Huang et al protection. While PPARa is highly expressed in liver, skeletal muscle, kidney, heart, and the vascular wall, PPARg is predominantly detected in adipose tissue, intestine, and macrophages. Peroxisome proliferator-activated receptor a and PPARg have different functions on regulating lipid metabolism, cell proliferation, and differentiation. Peroxisome proliferator-activated receptor a controls intracellular and extracellular lipid metabolisms, whereas PPARg triggers adipocyte differentiation and promotes lipid storage.
28
ERK1/2 and Akt signaling as well as oxidative stress-responsive transcription factors are known to induce MMP expression. 15 Our in vitro data showed that HIV-1-induced activation of MMP-9 was attenuated by blocking ERK and Akt signaling and that these effects were caveolae dependent. 15 Among a variety of cellular functions, MMPs (and in particular MMP-9) are involved in regulation of the BBB permeability and TJ integrity.
14 Therefore, part of the current studies was completed in MMP-9-deficient animals. We choose a genetic model of MMP-9 deficiency instead of MMP inhibitors because the nonselective nature of MMP inhibitors causes several side effects that hinder their therapeutic use. 29 The rationale for targeting MMP-9 was also made based on the observation that this MMP involved in the development of neuroinflammation. Indeed, increased MMP secretion was shown to be involved in HIV-1 exiting the blood stream and gaining access to body tissues, and serum MMP levels correlated with brain injury in patients with advanced HIV infection. 30 In addition, the neurotoxicity induced by Tat was inhibited by anti-MMP antibodies, but not by antibodies against Tat, indicating that Tat causes neuronal death through an indirect mechanism. 17 Our previous study indicated that Tat exposure upregulated MMP-9 protein levels in brain endothelial cells 14, 15 and administration of Tat into the ICA enhanced MMP-9 activity in plasma and protein expression in brain tissue. 19 The mechanisms by which MMPs disrupt the barrier integrity of the brain endothelium appear to involve degradation of specific TJ proteins; therefore, it was surprising to show in the present study that the baseline Figure 5 . Peroxisome proliferator-activated receptor (PPAR) agonists protect against HIV Tat-induced neuronal loss. The expression of NeuN was decreased in the cerebral cortex of the wild-type (WT) mice at the 24-hour time point after the single dose of HIV-1 Tat. These effects were attenuated by cotreatment with fenofibrate or rosiglitazone or in the matrix metalloproteinase-9 (MMP-9) knockout mice as detected by immunofluorescent staining (A) and western blotting (B). Images reflect representative data from at least three experiments. Results are the mean ± SEM. *Significantly different as compared with vehicle-treated controls in WT or MMP-9 À / À mice at Po0.05 or **Po0.01. expression of importantly TJ proteins, such as claudin-5 and ZO-1, was lower in MMP-9 knockout mice as compared with WT controls. Nevertheless, TJ proteins in MMP-9-deficient mice were inducible as shown by treatment with fenofibrate.
While microglia are the main CNS cell type productively infected by HIV, 31 recent evidence reevaluated the importance of astrocytes as the cells susceptible to HIV infection. 32 Using in situ PCR, it was considered that only 1% to 3% astrocytes are infected in HIV-infected brains. 33, 34 These findings were recently revised when up to 20% infected astrocytes were detected in brains of patients with HIV-associated dementia by combining double immunohistochemistry, laser capture microdissection, and highly sensitive multiplexed PCR. 32 The magnitude of astrocyte infection was also correlated with the severity of HIV-associated dementia and HIV-associated encephalitis. In addition, extensive reactive astrogliosis, neuronal loss, and formation of multinucleated giant cells from fusion of infected microglia are characteristic for the brain infection by HIV in AIDS patients. 35, 36 Several of these findings can be reproduced by exposing experimental animals to Tat protein. For example, reactive astrogliosis, which is considered as a pathologic hallmark of brain injury, 37 was found in the striatum as late as 7 days after a single microinjection of 50 mg Tat 1 to 72 into striatum via stereotaxic injection. 16 In the current study, Tat also induced a late effect on overexpression of GFAP, which was attenuated by PPAR agonists and MMP-9 deficiency.
An intact synaptodendritic network is vital for normal cognitive functioning. Even though HIV does not replicate in neurons, neuronal death and synaptodendritic degenerative changes highlight neurocognitive dysfunctions, which frequently develop during the CNS infection by HIV. 38 This phenomenon also illustrates the fact that neuronal dysfunction and death are not caused directly by HIV but rather result from indirect factors, such as release of viral proteins, inflammatory mediators, and other factors from infected cells. In the present study, injection of Tat into cerebral vasculature induced a prominent neuronal loss in WT mice. However, PPAR agonists and MMP-9 deficiency attenuated these effects, mirroring their influence on Tat-induced astrogliosis. Molecular mechanisms of interactions of PPAR agonists with MMP-9 are not fully understood. We showed that transcriptional regulation of MMP-9 expression requires functional caveolae and is modulated by PPARa or PPARg via ERK and Akt signaling. 14, 15 In addition, a recent study provided evidence that MMP-9 can be directly regulated by yet another PPAR isoform, PPARd. It was also showed that PPAR response element is present in the promoter region of MMP-9 at the location À 944 to À 921 bp and its binding to PPARd is responsible for transrepression of MMP-9 expression. 39 In conclusion, the results of the present study indicate the therapeutic properties of PPAR agonists in HIV-induced brain pathology with the focus on their protective effects against cerebrovascular toxicity. Interestingly, stimulation of PPARa activity appears to be more protective as compared with PPARg. Matrix metalloproteinase-9 deficiency further potentiated protective effects of PPARa agonists fenofibrate, indicating the importance of multitarget approach for a better protection against Tatinduced cerebrovascular damage.
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